Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

Time to Progression of Disease (TTP-Time To Progression, for ITT Set)

median TTP

Time frame: ICF (Informed Consent Form completed) to the date of objective progression or death (by any cause in the absence of progression)

Determination (for ITT Set): Median Survival

median overall survival (OS)

Time frame: ICF to the date of death

Determination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities

number of adverse events

Time frame: ICF to Last Patient Out (LPO)

Evaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits)

Patient-reported FACT-EN questionaire. Presented is the change from baseline after 12 visits/12 months. The overall total score of 43 single items was transformed to a scale from 0 to 100 (0 = worst level of well-being; 100 = highest level of well-being).

Time frame: ICF (Baseline) up to 12 months (12 visits)